Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion ...

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Positive, early results ...

Incyte ((INCY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today ...

Kura Oncology, Inc. announced the initiation of the KOMET-015 Phase 1 clinical trial, which will evaluate the safety and effectiveness of ziftomenib, an investigational menin inhibitor, in combination ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ara h 2 is bound to a cucumber mosaic vaccine so the ...

ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearance Results showed excellent consistency between ...